About US
Contact us
-
US Government’s new rule targets drug industry’s rebate systemUS Department of Health & Human Services (HHS) has proposed a new rule to end drug rebates and push direct discounts to patients across the country. The move is intended tolower the prices of pre2019/2/3
-
Merck obtains FDA breakthrough status for pneumococcal vaccineMerck has secured breakthrough designation from the US Food and Drug Administration (FDA) for its investigational 15-valent pneumococcal conjugate vaccine, V114. The company is developing the vaccine2019/2/2
-
Orphazyme publish good results for arimoclomol for NPCDanish drug maker Orphazyme has announced positive results from its Phase II/III trial of arimoclomol in rare genetic disease Niemann-Pick disease type C (NPC). The multi-centred, double-blind trial2019/2/2
-
Sanofi, Lilly and Novo face enquiry over high insulin prices in USDrug giants Sanofi, Eli Lilly and Novo Nordisk have been sent letters by US lawmakers requesting information on the increased costs of insulin in recent years and the companies’ profit from sales of t2019/2/1
-
Merck Group granted US patent for digital-enabled supply chain security methodGerman-based Merck Group has been granted a patent for creating ‘crypto-objects’ based on artificial intelligence (AI) and blockchain that can be used to secure pharmaceutical supply chains. The pate2019/2/1
-
Pfizer CEO: It'll be 2020 before issues in sterile injectables manufacturing are resolvedIt appears it will be another hard year for U.S. hospitals to get their hands on sterile injectables as work continues at Pfizer’s troubled plant in Kansas, perhaps the largest U.S. producer of the dr2019/1/31
-
Test run of drug prices in ads exposes a loophole—and pharma's already using itIt’s no surprise that listing the high price of a drug in advertisingwould discourage consumers. But add in an offer to help cover the cost—withcopay or coupon assistance—and viewers are fine with apr2019/1/31
-
Amgen hunts for deals of all sizes to combat forthcoming sales declineA couple of Big Pharma players have come out against megamergers in recent weeks. But Amgen isn’t one of them. On Tuesday’s fourth-quarter earnings conference call, CEO Bob Bradway said his company c2019/1/30
-
Pfizer's suffering from generics, but 'innovation for growth'—not big M&A—is still the mantraPfizer’s M&A strategy is always a topic of interest, but that interest has ramped up with the company’s recent CEO switch. So far, though, new chief Albert Bourla is sticking with the company line2019/1/30
-
Biogen executives fend off Alzheimer's questions with pipeline promises, deal talkIf there’s one thing that prompts hand-wringing amongst Wall Street analysts who cover Biogen, it’s the company’s reluctance to present interim data from ongoing clinical trials of its closely watched2019/1/29